Mikhail Kalinichev

Company: Neurosterix

Job title: Head of Translational Science

Seminars:

Transforming the Translational Validity of Preclinical Psychosis Models: Moving Beyond Dopamine-Focused Assays to Study New Anti-Psychosis Drug Mechanisms & Demonstrate Clinically Relevant Readouts 9:00 am

Current psychosis research often uses pharmacological models targeting dopamine but fails to capture the disorder's complexity. These models lack translational accuracy and overlook biological diversity among patients. Emerging research emphasizes the importance of integrative models that include glutamatergic, GABAergic, inflammatory, and neurodevelopmental mechanisms. There's increasing demand for validated biomarkers reflecting diverse mechanisms to improve patient…Read more

day: Pre-Conference Day

Animal Models of Psychosis – How to Show Antipsychotic Efficacy of Novel Drugs Based on Non-Dopaminergic Mechanisms 12:00 pm

In vivo efficacy of xanomeline: how well the studies in animals capture its antipsychotic profile in humans? In vivo efficacy of muscarinic M4 agonists and positive allosteric modulators: what did we learn so far? Potential gaps in understanding the antipsychotic potential of muscarinic potentiatorsRead more

day: Day Two